WO2013029446A1 - 螺环苄胺-膦和制备方法及其应用 - Google Patents
螺环苄胺-膦和制备方法及其应用 Download PDFInfo
- Publication number
- WO2013029446A1 WO2013029446A1 PCT/CN2012/079257 CN2012079257W WO2013029446A1 WO 2013029446 A1 WO2013029446 A1 WO 2013029446A1 CN 2012079257 W CN2012079257 W CN 2012079257W WO 2013029446 A1 WO2013029446 A1 WO 2013029446A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- phosphine
- sec
- benzylamine
- tert
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract description 16
- 229910000073 phosphorus hydride Inorganic materials 0.000 title abstract description 6
- -1 alpha-substituted acrylic acids Chemical class 0.000 claims abstract description 170
- 238000006243 chemical reaction Methods 0.000 claims abstract description 73
- 150000001450 anions Chemical class 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 239000002243 precursor Substances 0.000 claims abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 41
- SZVYQNDXXJQLHC-UHFFFAOYSA-N phenylmethanamine;phosphane Chemical compound P.NCC1=CC=CC=C1 SZVYQNDXXJQLHC-UHFFFAOYSA-N 0.000 claims description 34
- 239000003054 catalyst Substances 0.000 claims description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 239000012327 Ruthenium complex Substances 0.000 claims description 17
- 239000003446 ligand Substances 0.000 claims description 16
- 125000002252 acyl group Chemical group 0.000 claims description 15
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000003277 amino group Chemical group 0.000 claims description 11
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 125000002541 furyl group Chemical group 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 125000004423 acyloxy group Chemical group 0.000 claims description 9
- 125000004185 ester group Chemical group 0.000 claims description 9
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- 125000001624 naphthyl group Chemical group 0.000 claims description 9
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 9
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 8
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 229910052707 ruthenium Inorganic materials 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000003003 spiro group Chemical group 0.000 claims description 7
- RRKODOZNUZCUBN-CCAGOZQPSA-N (1z,3z)-cycloocta-1,3-diene Chemical compound C1CC\C=C/C=C\C1 RRKODOZNUZCUBN-CCAGOZQPSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 125000002723 alicyclic group Chemical group 0.000 claims description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 6
- 239000000460 chlorine Substances 0.000 claims description 5
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 5
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 4
- 239000005977 Ethylene Substances 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- SJYNFBVQFBRSIB-UHFFFAOYSA-N norbornadiene Chemical group C1=CC2C=CC1C2 SJYNFBVQFBRSIB-UHFFFAOYSA-N 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 3
- 125000004742 propyloxycarbonyl group Chemical group 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 159000000000 sodium salts Chemical group 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 2
- QTYUSOHYEPOHLV-FNORWQNLSA-N 1,3-Octadiene Chemical compound CCCC\C=C\C=C QTYUSOHYEPOHLV-FNORWQNLSA-N 0.000 claims description 2
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 claims description 2
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 238000005349 anion exchange Methods 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 claims description 2
- 150000007942 carboxylates Chemical class 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 229940125782 compound 2 Drugs 0.000 claims description 2
- 238000007333 cyanation reaction Methods 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 229940043279 diisopropylamine Drugs 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 claims description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005932 isopentyloxycarbonyl group Chemical group 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000005933 neopentyloxycarbonyl group Chemical group 0.000 claims description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 150000004714 phosphonium salts Chemical class 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 229960003975 potassium Drugs 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 229940093956 potassium carbonate Drugs 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 229940086066 potassium hydrogencarbonate Drugs 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 239000004332 silver Substances 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 2
- 125000005934 tert-pentyloxycarbonyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- ABVVEAHYODGCLZ-UHFFFAOYSA-N tridecan-1-amine Chemical compound CCCCCCCCCCCCCN ABVVEAHYODGCLZ-UHFFFAOYSA-N 0.000 claims description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- GUNJVIDCYZYFGV-UHFFFAOYSA-K antimony trifluoride Chemical compound F[Sb](F)F GUNJVIDCYZYFGV-UHFFFAOYSA-K 0.000 claims 2
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims 2
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 claims 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 2
- KHPNGCXABLTQFJ-UHFFFAOYSA-N 1,1,1-trichlorodecane Chemical compound CCCCCCCCCC(Cl)(Cl)Cl KHPNGCXABLTQFJ-UHFFFAOYSA-N 0.000 claims 1
- IXADHCVQNVXURI-UHFFFAOYSA-N 1,1-dichlorodecane Chemical compound CCCCCCCCCC(Cl)Cl IXADHCVQNVXURI-UHFFFAOYSA-N 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000004985 diamines Chemical class 0.000 claims 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 4
- 238000005342 ion exchange Methods 0.000 abstract description 2
- 229910052741 iridium Inorganic materials 0.000 abstract 3
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 abstract 3
- 238000005481 NMR spectroscopy Methods 0.000 description 50
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 46
- 235000019439 ethyl acetate Nutrition 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 14
- 230000008018 melting Effects 0.000 description 14
- 238000002844 melting Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- BTHBTTSIBCWHHH-UHFFFAOYSA-N 2-[4-(2-methylpropyl)phenyl]prop-2-enoic acid Chemical compound CC(C)CC1=CC=C(C(=C)C(O)=O)C=C1 BTHBTTSIBCWHHH-UHFFFAOYSA-N 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 238000000967 suction filtration Methods 0.000 description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical class C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000005356 chiral GC Methods 0.000 description 9
- 239000002274 desiccant Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000011914 asymmetric synthesis Methods 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 6
- 238000002390 rotary evaporation Methods 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 0 C*Cc1c(C(C(C)C2N)(C3C)c4c(*C)cccc4C3N)c2ccc1 Chemical compound C*Cc1c(C(C(C)C2N)(C3C)c4c(*C)cccc4C3N)c2ccc1 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000004808 supercritical fluid chromatography Methods 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- ZGRQPKYPJYNOKX-XUXIUFHCSA-N Cys-Cys-His-His Chemical compound C([C@H](NC(=O)[C@H](CS)NC(=O)[C@H](CS)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ZGRQPKYPJYNOKX-XUXIUFHCSA-N 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000004296 chiral HPLC Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- MROCJMGDEKINLD-UHFFFAOYSA-N dichlorosilane Chemical compound Cl[SiH2]Cl MROCJMGDEKINLD-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- HEFNNWSXXWATRW-SNVBAGLBSA-N levibuprofen Chemical compound CC(C)CC1=CC=C([C@@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-SNVBAGLBSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- 239000010948 rhodium Substances 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- ADDZHRRCUWNSCS-UHFFFAOYSA-N 2-Benzofurancarboxaldehyde Chemical compound C1=CC=C2OC(C=O)=CC2=C1 ADDZHRRCUWNSCS-UHFFFAOYSA-N 0.000 description 1
- IOAKCXIQQLGELH-UHFFFAOYSA-N 2-n,2-n-bis(sulfanyl)benzene-1,2-dicarboxamide Chemical compound NC(=O)C1=CC=CC=C1C(=O)N(S)S IOAKCXIQQLGELH-UHFFFAOYSA-N 0.000 description 1
- ZIQMBOJQMDWMLJ-UHFFFAOYSA-N 4,5-dihydro-1,3-oxazol-2-ylphosphane Chemical compound PC1=NCCO1 ZIQMBOJQMDWMLJ-UHFFFAOYSA-N 0.000 description 1
- USANCVVZOHSATA-UHFFFAOYSA-N C=C(CCc1ccccc1)C(O)=O Chemical compound C=C(CCc1ccccc1)C(O)=O USANCVVZOHSATA-UHFFFAOYSA-N 0.000 description 1
- OCKZHEXBLOOGOC-SECBINFHSA-N C[C@H](CCc1ccccc1)C(O)=O Chemical compound C[C@H](CCc1ccccc1)C(O)=O OCKZHEXBLOOGOC-SECBINFHSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000006612 decyloxy group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 229940093932 potassium hydroxide Drugs 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- CUQOHAYJWVTKDE-UHFFFAOYSA-N potassium;butan-1-olate Chemical compound [K+].CCCC[O-] CUQOHAYJWVTKDE-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical class O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 150000003303 ruthenium Chemical class 0.000 description 1
- 150000003304 ruthenium compounds Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- QRUBYZBWAOOHSV-UHFFFAOYSA-M silver trifluoromethanesulfonate Chemical compound [Ag+].[O-]S(=O)(=O)C(F)(F)F QRUBYZBWAOOHSV-UHFFFAOYSA-M 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0033—Iridium compounds
- C07F15/004—Iridium compounds without a metal-carbon linkage
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/18—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
- B01J31/189—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms containing both nitrogen and phosphorus as complexing atoms, including e.g. phosphino moieties, in one at least bidentate or bridging ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B35/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving a change in the type of bonding between two carbon atoms already directly linked
- C07B35/02—Reduction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B53/00—Asymmetric syntheses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/36—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by hydrogenation of carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0033—Iridium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/5022—Aromatic phosphines (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/505—Preparation; Separation; Purification; Stabilisation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/60—Reduction reactions, e.g. hydrogenation
- B01J2231/64—Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
- B01J2231/641—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
- B01J2231/645—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of C=C or C-C triple bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/827—Iridium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the invention relates to a novel spirocyclic benzylamine-phosphine and a preparation method thereof and application thereof.
- the present invention is synthesized by a two-step or three-step reaction using substituted 7-trifluorosulfonyloxy-7'-diarylphosphino-indole and anthracene-spirobihydroindole as starting materials. Said the new spiro benzylamine-phosphine.
- novel spirocyclic benzylamine-phosphine and ruthenium precursor are complexed, and then subjected to ion exchange to obtain a ruthenium/spirocyclic benzylamine-phosphine complex containing different anions.
- the novel spirocyclic benzylamine-phosphine ruthenium complex can catalyze the asymmetric hydrogenation of various ⁇ -substituted acrylic acids, exhibits high activity and enantioselectivity, and has good industrialization prospects.
- the key to catalytic asymmetric synthesis is the synthesis of chiral catalysts.
- the synthesis of chiral catalysts is based on the synthesis of chiral ligands, since chiral ligands are the source of asymmetric control of chiral catalysts.
- the design and synthesis of novel chiral ligands and catalysts are the driving force behind the development of catalytic asymmetric synthesis.
- Chiral carboxylic acids are widely used in the synthesis of pharmaceuticals and natural products and are an important class of synthetic building blocks.
- ⁇ -aryl substituted propionic acid such as naproxen and ibuprofen
- ibuprofen is a non-steroidal analgesic and anti-inflammatory drug widely used in the world today.
- the development of an efficient and highly selective synthesis of optically active ⁇ -substituted propionic acid has important application value.
- the asymmetric hydrogenation of transition metal catalyzed ⁇ -substituted acrylic acid is one of the most direct and effective methods for obtaining such compounds.
- the bisphosphine ligand and rhodium complex catalysts are also used for the asymmetric hydrogenation of alpha-substituted acrylic acid, although some rhodium catalysts achieve higher enantioselectivity in the asymmetric hydrogenation of alpha-aryl substituted acrylic acid,
- the amount of catalyst is relatively large (1 mol%) and has only moderate enantioselectivity for the ⁇ -alkyl substituted acrylic substrate (1. Robin, R; Mercier, R; Ricard, L.; Mathey, R; Spagnol, M Chem. Eur. J. 1997, 3, 1365; 2.
- the novel spirocyclic benzylamine-phosphine ruthenium complex can catalyze the asymmetric hydrogenation of various ⁇ -substituted acrylic acids, exhibits high activity and enantioselectivity, and has good industrialization prospects.
- the spirocyclic benzylamine-phosphine provided by the present invention has a compound of the formula (I):
- n 0 ⁇ 3;
- RR 2 is H, d ⁇ C 8 alkyl, haloalkyl, d ⁇ C 8 alkoxy, C 2 ⁇ C 8 acyloxy, d ⁇ C 8 acyl, C 2 ⁇ C 8 ester group, (d ⁇ C 8 acyl)amino group, di(C-poly( 8- alkyl)amino group, halogen, phenyl group, substituted phenyl group, naphthyl group, substituted decyl group, furyl group, thienyl group, or When 11 ⁇ 2, it is a alicyclic ring or an alicyclic ring; R 1 and R 2 may be the same or different;
- R 3 , R 4 , R 5 and R 6 are each independently H, C-C 8 alkyl, haloalkyl, C-C 8 alkoxy, C 2 -C 8 acyloxy, C-C 8 acyl, C 2 ⁇ C 8 ester group, (d ⁇ C 8 acyl)amino group, bis(C-C 8 alkyl)amino group, halogen, phenyl group, substituted phenyl group, naphthyl group, substituted decyl group, furyl group, thienyl group, Or R 3 ⁇ R 4 , R 5 ⁇ R e are a alicyclic or aromatic ring; R 3 , R 4 , R 5 , R 6 may be the same or different;
- ⁇ is ( ⁇ ( ⁇ alkyl, phenyl, substituted phenyl, zekeyl, substituted zeoliyl, furyl, thienyl;
- R 8 and R 9 are each independently H, d-C 8 alkyl, benzyl, substituted phenyl fluorenyl, phenyl, substituted phenyl, zekeyl, substituted decyl, furyl, thiamidine; R 8 And R 9 may be the same or different;
- the substituent is d-C 8 alkyl, d-C 8 alkoxy, hydroxy, C 2 -C 8 acyloxy, halogen, amino, (C-C 8 acyl) amino group. , di (C wide (38-alkyl) amino, C wide C 8 acyl, C 2 ⁇ C 8 ester groups of one or more; number of substituents is 0 to 5.
- the d ⁇ C 8 alkyl group is a mercapto group, an ethyl group, a n-propyl group, an isopropyl group, a n-butyl group, an isobutyl group, a sec-butyl group, a t-butyl group, a n-pentyl group, an isopentyl group, a neopentyl group.
- Base sec-pentyl, tert-amyl, n-hexyl, isohexyl, neohexyl, sec-hexyl, tert-hexyl, n-heptyl, isoheptyl, neoheptyl, sec-heptyl, tert-heptyl, n-octyl Base, isooctyl, neooctyl, sec-octyl or tertiary octyl;
- the d ⁇ c 8 alkoxy group is a decyloxy group, an ethoxy group, a n-propoxy group, an isopropoxy group, a n-butoxy group, an isobutoxy group, a sec-butoxy group, a tert-butoxy group, and a positive Pentyloxy, isopentyloxy, neopentyloxy, sec-pentyloxy, tert-pentyloxy, n-hexyloxy, isohexyloxy, neohexyloxy, sec-hexyloxy, tert-hexyloxy, n-heptyloxy , iso-heptyloxy, neoheptyloxy, sec-heptyloxy, tert-heptyloxy, n-octyloxy, isooctyloxy, neooctyloxy, sec-octyloxy or ter
- the CH ⁇ acyl group is a decanoyl group, an acetyl group, a propionyl group, a n-butyryl group, an isobutyryl group, a isovaleryl group, an isovaleryl group, a pivaloyl group, a pivaloyl group, a n-hexanoyl group, an isohexanoyl group, a neohexanoyl group, Secondary hexanoyl, n-heptanoyl, isoheptanoyl, neoheptanoyl, heptyl, n-octanoyl, isooctanoyl, neooctanoyl, sec-octanoyl, 1-cyclopropyldecanoyl, 1-cyclobutylhydrazine Acyl, 1-cyclopentyldecanoyl, 1-cyclohexy
- the C 2 -C 8 acyloxy group is acetoxy, propionyloxy, n-butyryloxy, isobutyryloxy, n-pentanoyloxy, isovaleryloxy, sec-pentanoyloxy, Pivaloyloxy, n-hexanoyloxy, isohexanoyloxy, neohexanoyloxy, sec-hexanoyloxy, n-heptanoyloxy, isoheptanoyloxy, neoheptanoyloxy, sec-heptanoyloxy , n-octanoyloxy, isooctanoyloxy, neooctanoyloxy, sec-octanoyloxy, 1-cyclopropylnonanoyloxy, 1-cyclobutylnonanoyloxy, 1-cyclopentyl a acyloxy group, a 1-cyclo
- the haloalkyl group is a haloalkyl group of fluorine, chlorine, bromine or iodine.
- the spirocyclic benzylamine-phosphine (I) of the present invention further comprises a racemate, a right-handed body and a left-handed body having the same chemical structural formula but having different stereo structures and optical rotation properties.
- the preparation method of the spirocyclic benzylamine-phosphine according to the present invention comprises the following steps:
- hydrazine-spirobihydroindole 1 as starting material, first preparing intermediate 2 by palladium-catalyzed cyanation reaction; The cyano compound 2 is subjected to a reducing agent to obtain a spirocyclic benzylamine-phosphine 3 in which R 8 and R 9 are simultaneously H; a substitution reaction is carried out on the amino group of spiro benzylamine-phosphine 3 to prepare R 8 and R 9 at different times.
- Other spiro benzylamine-phosphines which are H.
- n 0 to 3; the values of RR 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined in the above compound (I).
- the ruthenium complex 5 of spiro benzylamine-phosphine prepared by the spirocyclic benzylamine-phosphine provided by the present invention has the following structural formula:
- R 9 is as defined in claim 1;
- X is a halogen, a carboxylate of d to C 8 , a sulfate, a tetrakis(3,5 bistrifluorodecylphenyl)borate, a tetrakis(pentafluorophenyl) Boric acid, tetrakis(perfluoro-tert-butoxy)aluminum ion, tetrakis(hexafluoroisopropoxy)aluminum ion, hexafluorophosphate, hexafluoroantimonate, perchloric acid, tetrafluoroborate or trifluoromethyl Sulfonic acid.
- the cyclooctadiene ligand can be substituted with ethylene or norbornadiene.
- n 0 ⁇ 3; the values of RR 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X are as defined in claim 6; COD is 1,5-ring
- the octadiene; the cyclooctadiene ligand may be substituted with ethylene or norbornadiene; the sodium salt may be substituted with the corresponding potassium, ammonium, silver or phosphonium salt.
- [Ir] is a spirocyclic benzylamine-phosphine ruthenium complex according to claim 6;
- R 1G is d-C 8 alkyl, haloalkyl, benzyl, phenethyl, phenyl, substituted benzene group, a naphthyl group, a substituted Cai, furanyl, thiazolyl group Yu, C wide C 8 alkoxy, Yue phenyl group, a phenoxy group; a position marked with an asterisk is a chiral center.
- the specific process is: adding the catalyst and the substrate to the inner tube of the reaction vessel, adding the additive and the solvent, sealing the reaction vessel and replacing it with hydrogen for 3 to 10 times, charging the hydrogen to a specified pressure, and stirring the reaction at the specified temperature to the end;
- the catalytic hydrogenation reaction conditions are: the solvent used is d-C 6 alcohol; the amount of the catalyst is 0.001-1 mol%; the substrate concentration is 0.001 ⁇ 10.0 M; the additive is isopropylamine, tert-butylamine, diammonium, two Ethylamine, diisopropylamine, diisopropylethylamine, tridecylamine, triethylamine, 1,8-diazabicyclo[5,4,0]undec-7-ene, 1,4-di Azabicyclo[2,2,2]octane, sodium hydride, sodium hydroxide, sodium carbonate, sodium hydrogencarbonate, One or more of sodium t-butoxide, potassium hydroxide, potassium carbonate, potassium hydrogencarbonate, potassium t-butoxide, cesium hydroxide, cesium carbonate; reaction temperature is 0-100 ° C; hydrogen pressure is 0.1-10 MPa; reaction for 10 minutes to 48 hours.
- the invention adopts substituted 7-trifluorosulfonyloxy-7'-diarylphosphino-indole, anthracene-spirobihydroindole as a starting material, and synthesizes the novel invention according to the invention by two or three steps reaction.
- Spirocyclic benzylamine-phosphine Spirocyclic benzylamine-phosphine.
- the novel spirocyclic benzylamine-phosphine and ruthenium precursors are complexed and ion exchanged to obtain a ruthenium/spirocyclic benzylamine-phosphine complex containing different anions.
- novel spirocyclic benzylamine-phosphine ruthenium complex is capable of catalyzing the asymmetric hydrogenation of various ⁇ -substituted acrylic acids and exhibits the following characteristics: low working pressure (usually 0.6 MPa), even under normal pressure Asymmetric catalytic hydrogenation can be well done; the substrate has a wide range of applications, and it gives good results for ⁇ -aryl substituted acrylic acid and ⁇ -alkyl substituted acrylic acid; it is well tolerated by functional groups.
- the ester group, alkoxy group and aryloxy group in the chain do not affect the reaction result; the efficiency is 4 ⁇ , the conversion frequency can reach 6000 times/hour, the conversion number can reach 10000; the enantioselectivity can reach 99% ee.
- the above characteristics indicate that one of the most efficient ligands and catalysts for the asymmetric catalytic hydrogenation of the novel acid provided by the present invention has a good industrial prospect.
- the invention discloses a spirocyclic benzylamine-phosphine and a preparation method thereof and an application thereof, and those skilled in the art can learn from the contents of the paper and appropriately improve the process parameters. It is to be noted that all such alternatives and modifications will be apparent to those skilled in the art and are considered to be included in the present invention.
- the method and the application of the present invention have been described by the preferred embodiments, and it is obvious that the method and application described herein may be modified or appropriately modified and combined without departing from the scope of the present invention. The technique of the present invention is applied.
- Me is a mercapto group
- Et is an ethyl group
- Ph is a phenyl group
- An is a p-nonyloxyphenyl group
- Xyl is a 3,5-dimercaptophenyl group
- DTB is a 3,5-di-tert-butyl group.
- Base phenyl, BAr F is tetrakis(3,5-bistrifluorodecylphenyl)borate; OTf is trifluorosulfonate; C10 4 is perchlorate; BF 4 is tetrafluoroborate; PF 6 is Hexafluorophosphate; DMF is N,N-dimercaptophthalamide; THF is tetrahydrofuran; NMR is nuclear magnetic resonance, chiral HPLC is high performance liquid chromatography with chiral column, chiral SFC is equipped with hands Supercritical fluid chromatography of a chromatographic column, chiral GC is a gas chromatograph with a chiral capillary column; ee is the enantiomeric excess; S/C is the ratio of substrate to catalyst species.
- the solvent used is purified and dried by a common standard before use; the reagents used are either commercially available or synthesized according to the literature, and are pure in use.
- Example 1 Preparation of S 7-cyano-7'-bis(3,5-di-tert-butylphenyl)phosphino-indole, anthracene-spirobihydroindole
- the obtained solid was dissolved in 2 mL of dry tetrahydrofuran and cooled to about 0 ° C with an ice water bath. Subsequently, the tetrahydrofuran solution was carefully dropped into a suspension of LiAlH 4 (27 mg, 0.7 mmol) and 2 mL of tetrahydrofuran, heated to reflux in an oil bath, and the reaction was stirred overnight. The reaction was completely detected by TLC, and the organic layer was washed with a small amount of water. The mixture was diluted with 20 mL of ethyl acetate, and the organic layer was washed with 5% aqueous sodium hydroxide and brine. Dry over anhydrous sodium sulfate.
- HHRRMMSS ((MMAALLDDII)) ccaallccdd ffoorr CC 4422 HH 4488 IIrrNNPP ++ :: 779900..33115544 FFoouunndd 779900..33114488..
- the catalyst (0.0005 mmol) and 2-(4-isobutylphenyl)acrylic acid 6a (102 mg, 0.5 mmol) were weighed into a reaction tube equipped with a stirrer in a glove box and sealed for use. After taking out, cesium carbonate (82 mg, 0.25 mmol) and decyl alcohol (2 mL) were added, and the inner tube was placed in a hydrogenation reactor, and replaced with a hydrogen atmosphere by a pressurization-deflation operation (3 times 5 times). Set the hydrogen pressure to 0.6 MPa and stir the reaction at 45 °C until the pressure stops decreasing. Then, the stirring was stopped, the hydrogen gas was released, and the reaction system was evaporated to dryness.
- Catalyst CS 5a (0.9 mg, 0.0005 mmol) and 2-(4-isobutylphenyl)acrylic acid 6a (102 mg, 0.5 mmol) were weighed into a reaction tube containing a stir bar in a glove box and sealed for use. . After taking out, cesium carbonate (82 mg, 0.25 mmol) and decyl alcohol (2 mL) were added, and the inner tube was placed in a hydrogenation reactor, and replaced with a hydrogen atmosphere by a pressurization-deflation operation (3 times 5 times). The hydrogen pressure was set to 0.6 MPa, and the reaction was stirred at different temperatures until the pressure stopped decreasing.
- Catalyst CS 5a (0.9 mg, 0.0005 mmol) and 2-(4-isobutylphenyl)acrylic acid 6a (102 mg, 0.5 mmol) were weighed into a reaction tube containing a stir bar in a glove box and sealed for use. . After taking out, cesium carbonate (82 mg, 0.25 mmol) and decyl alcohol (2 mL) were added, and the inner tube was placed in a hydrogenation reactor, and replaced with a hydrogen atmosphere by a pressurization-deflation operation (3 times 5 times). Set the corresponding hydrogen pressure and stir the reaction at 45 °C until the pressure stops decreasing. Then, the stirring was stopped, the hydrogen gas was released, and the reaction system was evaporated to dryness.
- cesium carbonate (82 mg, 0.25 mmol) and decyl alcohol (2 mL) were added, and the inner tube was placed in a hydrogenation reactor, and replaced with a hydrogen atmosphere by a pressurization-deflation operation (3 times 5 times
- Catalyst CS 5a (0.9 mg, 0.0005 mmol) and 2-(4-isobutylphenyl)acrylic acid 6a (102 mg, 0.5 mmol) were weighed into a reaction tube containing a stir bar in a glove box and sealed for use. . After taking out, add different additives (0.25 mmol) and decyl alcohol (2 mL), place the inner tube in the hydrogenation reactor, replace it with hydrogen atmosphere by pressurization-deflation operation (3 times 5 times), and finally set hydrogen gas. The pressure is 0.6 MPa, The reaction was stirred at 45 ° C until the pressure stopped dropping. Then, the stirring was stopped, the hydrogen gas was released, and the reaction system was evaporated to dryness.
- 2-(4-Isobutylphenyl)acrylic acid 6a (204 mg, 1 mmol), cesium carbonate (164 mg, 0.5 mmol) and decyl alcohol (4 mL) were sequentially added to the inner tube, and the inner tube was placed in hydrogenated In the reaction vessel, the hydrogen gas atmosphere was replaced by a pressurization-deflation operation (3,05 times), and finally, the hydrogen pressure was set to 0.6 MPa, and the reaction was stirred at 45 ° C until the pressure stopped decreasing. Then stop stirring, release hydrogen, and then condense and concentrate the reaction system, adjust the pH of the system to 3 with 3 N hydrochloric acid aqueous solution, and use ether (10 mLx3).
- a catalyst CS 5a (1.1 mg, 0.0006 mmol) was weighed into a reaction inner tube equipped with a stir bar, and 12 mL of decyl alcohol was added thereto, and stirred to sufficiently dissolve. 10 mL of the catalyst solution was taken out, and then the remaining 2 mL of the solution was added with triethylamine (700 /L), decyl alcohol (2 mL), and 2-(4-isobutylphenyl)acrylic acid 6a ( 204 mg, 1 mmol).
- the inner tube was placed in a hydrogenation reactor, and was replaced with a hydrogen atmosphere by a pressurization-deflation operation (three times of five times), and finally, the hydrogen pressure was set to 0.6 MPa, and the mixture was stirred at 60 ° C until the pressure stopped decreasing. Then, the stirring was stopped, the hydrogen gas was released, and the reaction system was evaporated to dryness. The mixture was evaporated to dryness eluted with ethyl acetate (3 mL), and the organic phase was combined, washed with saturated brine and dried over anhydrous sodium sulfate. The desiccant was removed by suction filtration, and the mixture was evaporated to give the desired product (R)-7a as a white solid. After conversion to the corresponding oxime ester, the chiral GC analysis showed an ee value of 97%.
- Example 12 Hydrogenation of ⁇ -substituted acrylic acid under a hydrogen pressure of 0.6 MPa 0.1 mol % (S)-5a Me
- the desiccant was removed by suction filtration, and the product was obtained by rotary evaporation to give the desired product, and the conversion was carried out by NMR analysis, and all the reactions were completely converted.
- the ee value was analyzed by chiral GC, chiral HPLC or chiral SFC after conversion of the product to the corresponding oxime ester or amide. The experimental results obtained are shown in Table 6.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014527472A JP5968439B2 (ja) | 2011-08-31 | 2012-07-27 | スピロベンジルアミン−ホスフィン及びその製造方法並びにその使用 |
US14/240,918 US9108995B2 (en) | 2011-08-31 | 2012-07-27 | Spirobenzylamine-phosphine, preparation method therefor and use thereof |
EP12828043.5A EP2752419B1 (en) | 2011-08-31 | 2012-07-27 | Spirobenzylamine-phosphine, preparation method therefor and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110252000.7 | 2011-08-31 | ||
CN201110252000.7A CN102391306B (zh) | 2011-08-31 | 2011-08-31 | 螺环苄胺-膦和制备方法及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013029446A1 true WO2013029446A1 (zh) | 2013-03-07 |
Family
ID=45858707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2012/079257 WO2013029446A1 (zh) | 2011-08-31 | 2012-07-27 | 螺环苄胺-膦和制备方法及其应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9108995B2 (zh) |
EP (1) | EP2752419B1 (zh) |
JP (1) | JP5968439B2 (zh) |
CN (1) | CN102391306B (zh) |
WO (1) | WO2013029446A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102391306B (zh) | 2011-08-31 | 2014-09-03 | 浙江九洲药业股份有限公司 | 螺环苄胺-膦和制备方法及其应用 |
CN104892672B (zh) * | 2015-05-15 | 2018-09-21 | 浙江九洲药业股份有限公司 | 手性螺环膦-氮-硫三齿配体及其制备方法和应用 |
CN106518931B (zh) * | 2016-10-27 | 2021-08-24 | 南开大学 | 一种新型螺环膦-羧酸的铱络合物及其制备方法和应用 |
CN111410604B (zh) * | 2019-01-08 | 2023-06-16 | 浙江九洲药业股份有限公司 | 烯酸类化合物的不对称氢化反应 |
CN115197145B (zh) * | 2021-04-14 | 2024-02-13 | 西湖大学 | 手性螺环铵盐化合物及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5144050A (en) | 1991-10-01 | 1992-09-01 | Monsanto Company | Ruthenium(II)-BINAP diketonate complexes |
CN101671365A (zh) * | 2009-09-18 | 2010-03-17 | 南开大学 | 手性螺环胺基膦配体化合物与合成方法及其应用 |
CN102040625A (zh) * | 2010-11-19 | 2011-05-04 | 南开大学 | 手性螺环吡啶胺基膦配体化合物与合成方法及其应用 |
CN102391306A (zh) * | 2011-08-31 | 2012-03-28 | 南开大学 | 螺环苄胺-膦和制备方法及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100432083C (zh) * | 2006-07-11 | 2008-11-12 | 南开大学 | 螺环膦-噁唑啉配体及其在不对称催化氢化中的应用 |
CN101565366B (zh) * | 2008-04-25 | 2013-04-17 | 浙江九洲药业股份有限公司 | 铱络合物在不饱和羧酸不对称催化氢化中的应用 |
CN101565434B (zh) * | 2008-04-25 | 2012-05-30 | 浙江九洲药业股份有限公司 | 螺环膦-噁唑啉和制备方法及其应用 |
-
2011
- 2011-08-31 CN CN201110252000.7A patent/CN102391306B/zh active Active
-
2012
- 2012-07-27 US US14/240,918 patent/US9108995B2/en active Active
- 2012-07-27 WO PCT/CN2012/079257 patent/WO2013029446A1/zh active Application Filing
- 2012-07-27 JP JP2014527472A patent/JP5968439B2/ja active Active
- 2012-07-27 EP EP12828043.5A patent/EP2752419B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5144050A (en) | 1991-10-01 | 1992-09-01 | Monsanto Company | Ruthenium(II)-BINAP diketonate complexes |
CN101671365A (zh) * | 2009-09-18 | 2010-03-17 | 南开大学 | 手性螺环胺基膦配体化合物与合成方法及其应用 |
CN102040625A (zh) * | 2010-11-19 | 2011-05-04 | 南开大学 | 手性螺环吡啶胺基膦配体化合物与合成方法及其应用 |
CN102391306A (zh) * | 2011-08-31 | 2012-03-28 | 南开大学 | 螺环苄胺-膦和制备方法及其应用 |
Non-Patent Citations (12)
Title |
---|
BENINCORI, T.; BRENNA, E.; SANNICOLO, F.; TRIMARCO, L.; ANTOGNAZZA, P.; CESAROTTI, E.; DEMARTIN, F.; PILATI, T., J. ORG. CHEM., vol. 61, 1996, pages 6244 |
HU, W.-H.; PAI, C. C.; CHEN, C. C.; XUE, G.-P.; CHAN, A. S. C., TETRAHEDRON: ASYMMETRY, vol. 9, 1998, pages 3241 |
OHKUMA,T; KITAMURA,M.; NOYORI,R.: "Catalytic Asymmetry Synthesis", 2000, WILEY |
OHTA, T.; TAKAYA, H.; KITAMURA, M.; NAGAI, K.; NOYORI, R., J. ORG. CHEM., vol. 52, 1987, pages 3174 |
PAI, C.-C.; LIN, C.-W.; LIN, C.-C.; CHEN, C.-C.; CHAN, A. S. C., J. AM. CHEM. SOC., vol. 122, 2000, pages 11513 |
QIU, L.; WU, J.; CHAN, S.; AU-YEUNG, T. T.-L.; JI, J.-X.; GUO, R.; PAI, C.-C.; ZHOU, Z.; LI, X.; FAN, Q.-H., PROC. NATL. ACAD. SCI. U. S. A., vol. 101, 2004, pages 5815 |
ROBIN, F.; MERCIER, F.; RICARD, L.; MATHEY, F.; SPAGNOL, M., CHEM. EUR. J., vol. 3, 1997, pages 1365 |
SCRIVANTI, A.; BOVO, S.; CIAPPA, A.; MATTEOLI, U., TETRAHEDRON LETT., vol. 47, 2006, pages 9261 |
See also references of EP2752419A4 |
XIE, JIAN-HUA ET AL.: "An Additional Coordination Group Leads to Extremely Efficient Chiral Iridium Catalysts for Asymmetric Hydrogenation of Ketones", ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, vol. 50, no. 32, 12 July 2011 (2011-07-12), pages 7329 - 7332, XP055060237 * |
ZHANG, Y.; HAN, Z.-B.; LI, F.-Y.; DING, K.-L.; ZHANG, A., CHEM. COMMUN., vol. 46, 2010, pages 156 |
ZUPANCIC, B.; MOHAR, B.; STEPHAN, M., ORG. LETT., vol. 12, 2010, pages 3022 |
Also Published As
Publication number | Publication date |
---|---|
US20140194638A1 (en) | 2014-07-10 |
EP2752419A4 (en) | 2015-04-29 |
EP2752419B1 (en) | 2019-01-02 |
EP2752419A1 (en) | 2014-07-09 |
CN102391306A (zh) | 2012-03-28 |
CN102391306B (zh) | 2014-09-03 |
JP2014527534A (ja) | 2014-10-16 |
JP5968439B2 (ja) | 2016-08-10 |
US9108995B2 (en) | 2015-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5923105B2 (ja) | キラルスピロ−ピリジルアミドフォスフィン配位子化合物、その合成方法及びその利用 | |
CN101565434B (zh) | 螺环膦-噁唑啉和制备方法及其应用 | |
ES2585484T3 (es) | Aplicación de un complejo de iridio en la hidrogenación catalítica asimétrica de ácidos carboxílicos insaturados | |
WO2013029446A1 (zh) | 螺环苄胺-膦和制备方法及其应用 | |
WO2007007646A1 (ja) | 均一系不斉水素化反応用触媒 | |
Jha | Catalytic, enantioselective michael addition reaction | |
JP2016523972A (ja) | 新規なキラル窒素−リン配位子及びアルケン類の不斉水素化のためのその使用 | |
Wang et al. | Applications of conformational design: rational design of chiral ligands derived from a common chiral source for highly enantioselective preparations of (R)-and (S)-enantiomers of secondary alcohols | |
CN114394923B (zh) | 一种n-酰基-2-烷基吲哚啉化合物的制备方法 | |
JPWO2012137460A1 (ja) | 新規ルテニウム錯体及びこれを触媒とする光学活性アルコール化合物の製造方法 | |
JP6476497B2 (ja) | 光学活性化合物の製造方法、及び新規な金属−ジアミン錯体 | |
JP6940481B2 (ja) | 四座配位子、その製造方法及び合成中間体並びにその遷移金属錯体 | |
JP2000136193A (ja) | 光学活性ビスホスフィノメタン並びにそれらのロジウム又は銅錯体を用いる不斉合成 | |
CN114426560A (zh) | 一种手性双膦配体及其铑配合物和制备方法及其应用 | |
CN107880022B (zh) | 一种手性含咪唑吡啶酰胺类的化合物及其制备方法和应用 | |
Doran et al. | Neutral vs. cationic rhodium (I) complexes of bulky N-phosphino sulfinamide ligands: Coordination modes and its influence in the asymmetric hydrogenation of Z-MAC | |
CN106518931B (zh) | 一种新型螺环膦-羧酸的铱络合物及其制备方法和应用 | |
CN111039767A (zh) | 一种三唑卡宾催化制备氘代醛的方法 | |
US9340519B2 (en) | Paracyclophane-based ligands, their preparation and use in catalysis | |
CN109810056B (zh) | S-烷基-s-喹啉基-n-磺酰基氮硫叶立德化合物及其制备和应用 | |
US20240109832A1 (en) | Rapid construction of tetralin, chromane, and indane motifs via cyclative c-h/c-h coupling: four-step total synthesis of (±)-russujaponol f | |
WO2008044702A1 (fr) | Procédé de production d'un dérivé azabicycloalcanol | |
Jagtap et al. | Achiral and chiral NNN-pincer nickel complexes with oxazolinyl backbones: application in transfer hydrogenation of ketones | |
CN115650878A (zh) | 一种3-甲基取代的高烯丙基腈类化合物的合成方法 | |
Zhao | Novel sulfoxide ligands for Rh-catalysed dddition reactions of organoboron nucleophiles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12828043 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012828043 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14240918 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2014527472 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |